Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + Cisplatin + Etoposide in Extensive Disease SCLC
NCT00537511Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Feb 2008
- Primary completion
- Nov 2010
- Countries
- 2
01
Overview
Phase 2, open-label trial of pomalidomide in small cell lung cancer (SCLC), sponsored by Celgene Corporation. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Feb 2008; status: terminated.
02
Drugs
pomalidomide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00537511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00537511.